Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial.
about
Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesisExacerbated inflammatory cellular immune response characteristics of HAM/TSP is observed in a large proportion of HTLV-I asymptomatic carriersTetraspanins in viral infections: a fundamental role in viral biology?Ciclosporin A proof of concept study in patients with active, progressive HTLV-1 associated myelopathy/tropical spastic paraparesisTreatment of HTLV-I-Associated Myelopathy / Tropical Spastic Paraparesis: Towards Rational Targeted TherapyPathogenesis and treatment of HTLV-I associated myelopathy.Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseasesImmunopathogenesis of HTLV-I-associated myelopathy/tropical spastic paraparesis.Ascorbic acid has superior ex vivo antiproliferative, cell death-inducing and immunomodulatory effects over IFN-α in HTLV-1-associated myelopathyFunctional activity of monocytes and macrophages in HTLV-1 infected subjects.A Caucasian Australian presenting with human T-lymphotropic virus type I associated myelopathy: a case reportZidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial.HTLV-1 and innate immunity.Post-transplantation HTLV-1 myelopathy in three recipients from a single donor.A reduction of viral mRNA, proteins and induction of altered morphogenesis reveals the anti-HTLV-1 activity of the labdane-diterpene myriadenolide in vitro.Effect of Pulsed Methylprednisolone on Pain, in Patients with HTLV-1-Associated Myelopathy.Triple Therapy with Prednisolone, Pegylated Interferon and Sodium Valproate Improves Clinical Outcome and Reduces Human T-Cell Leukemia Virus Type 1 (HTLV-1) Proviral Load, Tax and HBZ mRNA Expression in Patients with HTLV-1-Associated Myelopathy/TrInterferon Beta-1a Improves Urinary Symptoms, Reduces Proviral Load, and Modifies the Immune Response in a Patient with HAM/TSP.Immunological and viral features in patients with overactive bladder associated with human T-cell lymphotropic virus type 1 infectionImmunopathogenesis of human T-cell leukemia virus type-1-associated myelopathy/tropical spastic paraparesis: recent perspectivesIn vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP)Cytokine Therapies in Neurological Disease.Severity score system for progressive myelopathy: development and validation of a new clinical scale.Timed walk as primary outcome measure of treatment response in clinical trials for HTLV-1-associated myelopathy: a feasibility study.CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis.Neuroimmunological aspects of human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis.Inflammatory manifestations of HTLV-1 and their therapeutic options.Molecular and clinical effects of betamethasone in human T-cell lymphotropic virus type-I-associated myelopathy/tropical spastic paraparesis patients.Human T-lymphotropic virus 1 neurologic disease.Evaluation of T Regulatory Lymphocytes Transcription Factors in HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Patients.Human T cell lymphotropic virus type 1 (HTLV-1) proviral load of HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients according to new diagnostic criteria of HAM/TSP.Alpha interferon restricts human T-lymphotropic virus type 1 and 2 de novo infection through PKR activation.The roles of acquired and innate immunity in human T-cell leukemia virus type 1-mediated diseases.HTLV-1-associated myelopathy in a solid organ transplant recipient.Association of cytokines, neurological disability, and disease duration in HAM/TSP patients.Pathogenesis and treatment of human T-cell lymphotropic virus Type I-associated myelopathy.Infective dermatitis has similar immunological features to human T lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis.Interferon-beta1a therapy in human T-lymphotropic virus type I-associated neurologic disease.Modulation of T cell responses in HTLV-1 carriers and in patients with myelopathy associated with HTLV-1.Clinical features of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in northeast Iran.
P2860
Q21131133-2844B479-F57C-4B65-B63E-DAC3A3A6A0F5Q24803711-2FBB3705-625B-4033-9536-0FC954EAF79EQ27470936-2878047C-1B9E-4896-ADEE-5364EC4491EAQ28484214-4EA17ED4-1B01-4705-ACFB-01F50B01F12DQ28972318-215E8D71-05B6-42C7-8934-6EC4F254DD1DQ33589322-4407C67A-7E96-4BB6-BD46-B6F28F77DCAAQ33983161-311BFD0E-81AC-4B4F-9370-FEBD8554E0FDQ34157538-80C33D25-F183-459D-AC01-DF96CE6AB4BAQ34359754-06709E56-8960-4D42-BE99-BC883F5E522AQ34733818-BAD16DA3-21CA-4472-9346-59C49D265282Q34768314-26BD625A-24E5-4926-9D3D-BEB71B1F3324Q35065987-AEB78640-8563-4FB8-B755-6D8639A8E210Q35261692-F96FA67D-F99E-4544-9959-B7E7B49E8F89Q35475269-0774311D-7D54-46FE-A209-73C2542594CDQ35533869-897B5ED8-A29E-4132-87B7-AB2B16A8D15BQ35989638-D442FFA3-6090-4E47-B02D-7034ACECEF2EQ36157642-26FF1B53-B6C6-4C3F-BDF7-E9C2ABD3C846Q36199924-86AE7796-E89B-44EB-9DFB-7192F7768127Q36277748-0A7A1E31-EEE2-446E-9831-0B81C505709CQ36422111-748A1F21-BAA3-4A1F-8B06-619E45E48374Q37122656-D310FA32-1A8F-42DC-A3B5-2EF31E060B1AQ37136498-C9FA97D8-F566-4123-BFC0-B740BD95B52DQ37371116-A1113F60-85F5-4985-8BB6-BEA54EF67736Q37498121-E5FD5394-A550-4245-8965-60641E7CD0D5Q37579811-622AEF24-124F-4366-9007-3E72F779530DQ38128799-DD19C83A-D86A-4C19-945A-EB1363DD729AQ38262169-F3D2AD74-B823-43BD-A9D0-5F10403E5624Q38867574-66522BBD-59AA-4D68-B232-8DC172D1171CQ38878539-851AD044-37AF-4629-AE0A-3AB19B91C6F6Q39022203-F063445D-4A05-4949-BD51-A92B6A9B3934Q39031445-2177A42F-F90C-4A7E-BEA2-BB20CD62E36AQ39088537-517CA5CD-0F5F-4AA9-A3CE-A7C7C98F3C38Q39119670-2E0E860B-AC56-4554-B895-447D250F7A8DQ39264203-4D46410F-2C96-44CE-A890-386D6ABC8FCCQ39281198-9C2D9D80-C6CA-4DBD-A64B-9163CFE320F3Q39289873-2E562672-4A6D-49DF-8564-4A345394C861Q39294381-AC945B87-7BC3-4262-8230-7B6B3E2571ECQ39318382-E9C538DA-097D-4103-B221-377D620387CBQ39430207-DC785520-52A5-4155-A866-DAFC97CBA9F8Q39459002-320489EC-7DC8-4628-9683-BD312C14707E
P2860
Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Interferon-alpha is effective ...... ouble-blind, controlled trial.
@en
Interferon-alpha is effective ...... ouble-blind, controlled trial.
@nl
type
label
Interferon-alpha is effective ...... ouble-blind, controlled trial.
@en
Interferon-alpha is effective ...... ouble-blind, controlled trial.
@nl
prefLabel
Interferon-alpha is effective ...... ouble-blind, controlled trial.
@en
Interferon-alpha is effective ...... ouble-blind, controlled trial.
@nl
P2093
P356
P1433
P1476
Interferon-alpha is effective ...... ouble-blind, controlled trial.
@en
P2093
Matsukura S
Nagataki S
Nakagawa M
P304
P356
10.1212/WNL.46.4.1016
P407
P577
1996-04-01T00:00:00Z